Induction Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Summary

The purpose of this study is to compare induction chemotherapy (docetaxel+cisplatin+fluorouracil) plus concurrent chemoradiotherapy with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma (NPC), in order to confirm the value of induction chemotherapy in NPC patients.

Conditions

• Nasopharyngeal Carcinoma

Interventions

DRUG

Docetaxel, cisplatin and fluorouracil

Patients receive docetaxel (60mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.

RADIATION

Concurrent chemoradiotherapy

Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.

Sponsors & Collaborators

• Fudan University

  collaborator OTHER

• West China Hospital

  collaborator OTHER

• Huazhong University of Science and Technology

  collaborator OTHER

• Peking University Cancer Hospital & Institute

  collaborator OTHER

• Zhejiang Cancer Hospital

  collaborator OTHER

• Central South University

  collaborator OTHER

• Jiangsu Cancer Institute & Hospital

  collaborator OTHER

• First People's Hospital of Foshan

  collaborator OTHER

• The Third Affiliated Hospital of Harbin Medical University

  collaborator OTHER

• Cancer Hospital of Guangxi Medical University

  collaborator OTHER

• Jiangxi Provincial Cancer Hospital

  collaborator OTHER

• Guangzhou Medical University

  collaborator OTHER

• Sun Yat-sen University

  lead OTHER

Principal Investigators

• Jun Ma, M.D. · Sun Yat-sen University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

59 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2011-01-31

Primary Completion

2016-04-30

Completion

2018-04-30

Countries

• China

Study Locations